Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Luohengfang for unstable angina pectoris (RCT)
ChiCTR2300075020Phase 3Not yet recruiting
- Sponsor
- Dongzhimen Hospital of Beijing University of Traditional Chinese Medicine
- Start
- Aug 2023
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in unstable angina and coronary arteriosclerosis comparing Control group: guideline-based therapy + placebo with Experimental group: guideline-based therapy + Luohengfang (2 arms). Primary endpoint: Seattle Angina Pectoris Scale (SAQ) score. Planned start Aug 2023; status: not yet recruiting.
02
Drugs
Fufang Zijing Xiaoshang Babugao
03
Conditions
unstable anginacoronary arteriosclerosis
Beyond the preview
Go deeper on ChiCTR2300075020.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300075020.